Mizuho raised the firm’s price target on BrightSpring Health (BTSG) to $22 from $20 and keeps an Outperform rating on the shares in conjunction with publishing the firm’s 2025 outlook note for managed care, acute care, behavioral health, clinical labs, clinical research organizations, physician services, post-acute care, retail pharmacies, and surgery centers. The firm believes the two main themes for all of those subsectors is whether the demand environment is durable and what, if any, is the regulatory risk/benefit from the new administration in Washington, the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $20 from $19 at Morgan Stanley
- BrightSpring Health initiated with an Outperform at CJS Securities
- BrightSpring Health Services Achieves Major Loan Refinancing
- BrightSpring Health price target raised to $21 from $19 at BofA
- BrightSpring Health price target raised to $21 from $17 at Wells Fargo